NeurologyOnline.net

Neurology Xagena

Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented at the European Committee for Research and Treatment in Multiple Sclerosis ...


The full results from the phase 3 DECIDE clinical trial have shown a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis ( RRMS ) w ...


The phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis ( RMS ) met the primary endpoint, reduction in MRI brain lesion activity. ...


The prognostic significance of age and continuous positive airway pressure ( CPAP ) therapy on cardiovascular disease in patients with sleep apnoea has not been assessed previously. Using nationwid ...


It is studied the applicability of the Acute Physiology and Chronic Health Evaluation II ( APACHE II ) and Simplified Acute Physiology Score II ( SAPS II ) in patients admitted to the intensive care u ...


The FDA-approved trial, A Phase 1, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Scler ...


A study has evaluated the ability of Lithium carbonate and Valproate cotreatment to modify the survival rate and functional score of patients with definite sporadic amyotrophic lateral sclerosis ( ALS ...


In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received Daclizumab high-yield process ( HYP ) for 52 weeks. The primary aim of the SELECTION extension st ...


Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. Researchers have assessed whether uric acid therapy would improve functional outcomes at 90 days in patients ...


Parkinson's disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson's disease. Researchers have assessed safety and efficacy of Pimavans ...


A retrospective cohort study using data from a large scale, comprehensive population based state-wide stroke registry in Germany, has assessed the time dependent effectiveness of thrombolytic therapy ...


Although the benefit of reducing blood pressure for primary and secondary prevention of stroke has been established, the effect of antihypertensive treatment in patients with acute ischemic stroke is ...


Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. The ...


There is insufficient evidence to support use of occupational therapy interventions for patients with Parkinson's disease. A study has assessed the efficacy of occupational therapy in improving daily ...


Autoimmunity might be associated with or implicated in sleep and neurodegenerative disorders. Researchers have described the features of a novel neurological syndrome associated with prominent sleep d ...


Fingolimod ( Gilenya ) has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. The FREEDOMS II has further assessed the efficacy and safety ...


There is some evidence to suggest a possible increased risk of complications when ancillary wound closure products are used in combination with collagen duraplasty grafts, including Durepair. As of O ...


New magnetic resonance imaging ( MRI ) data from the Lemtrada ( Alemtuzumab ) clinical development program were presented at the 66th American Academy of Neurology ( AAN ) Annual Meeting. In Alemtuzu ...


The benefits of intravenous tissue plasminogen activator ( tPA ) in patients with acute ischemic stroke are time dependent and guidelines recommend a door-to-needle ( DTN ) time of 60 minutes or less. ...


Acetazolamide ( Diamox ) is commonly used to treat idiopathic intracranial hypertension ( IIH ), but there is insufficient information to establish an evidence base for its use. IIHTT ( Idiopathic ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati